Scientific Advisory Board
We are a small company with big relationships.
SCIENTIFIC ADVISORY BOARD
DOUG ARNOLD ,MD
Douglas Arnold, MD is a Professor in the Department of Neurology and Neurosurgery at McGill University, Director of the Magnetic Resonance Spectroscopy Unit in the Brain Imaging Center at the Montreal Neurological Institute, and President of NeuroRx Research, a CNS imaging CRO. He has special expertise in advanced MRI acquisition and analysis techniques, particularly as they relate to understanding the evolution of multiple sclerosis and the measurement of markers of inflammation, remyelination and neuroprotection.
MYLA GOLDMAN, MD
Myla D Goldman, MD, MSc, is director of the James Q Miller Multiple Sclerosis (MS) Clinic, Chief MS/Neuroimmunology Division and Associate Professor of Neurology at the University of Virginia School of Medicine in Charlottesville, Va. Dr. Goldman’s special expertise are clinical research and trial design. Her research interests include MS therapeutics and MS-related ambulatory outcome measures.
JEFFREY COHEN, M.D.
BRUCE TRAPP, PH.D.
Scientific AdvisorProfessor and Chairman, Department of Neurosciences, Cleveland Clinic Foundation. Recipient of awards including the Harry Weaver Neuroscience Scholar Award from the National Multiple Sclerosis Society (NMSS) and the John Dystel Prize for MS Research from the American Academy of Neurology and the NMSS.
Dr. Michael Levy, M.D., Ph.D.
Dr. Michael Levy, MD, PhD, is an Assistant Professor of Neurology at the Johns Hopkins University and Director of the Neuromyelitis Optica Clinic.
Dr. Levy specializes in caring for patients with rare neuroimmunologic diseases including neuromyelitis optica, transverse myelitis and recurrent optic neuritis. In addition to four monthly clinics, Dr. Levy is the Principal Investigator on several clinical studies and drug trials for these conditions.
Upon completing the MD/PhD program at Baylor College of Medicine (Houston, TX) with a focus on neuroscience, Dr. Levy came to Johns Hopkins in 2004 for a 1-year internship in the Osler Medicine program followed by a 3 year residency in the Hopkins neurology program and a 2 year fellowship in Neuroimmunology. In 2009, Dr. Levy was appointed to the faculty as Assistant Professor.
Benjamin M. Greenberg, M.D., M.H.S., is an Associate Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology and Neurotherapeutics and the Department of Pediatrics at UT Southwestern Medical Center.
He received a Bachelor’s Degree in the History of Medicine from The Johns Hopkins University and a Master of Health Sciences Degree for the Johns Hopkins School of Public Health. From there, he received his MD from Baylor College of Medicine and went on to do an internship in Internal Medicine at Rush-St Lukes-Presbyterian Hospital in Chicago, Il. He completed a residency in Neurology and served as a Chief Resident at Johns Hopkins Hospital.
Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-director of the nation’s first dedicated Transverse Myelitis Center.
Dr. Greenberg is an internationally recognized expert in treating rare autoimmune disorders of the central nervous system. He is the principal investigator for the first large scale study of pediatric TM, coordinator centers throughout North America in a collaborative effort to better understand this rare disease.
He serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program, and the Pediatric Demyelinating Disease Program at Children’s Medical Center. He is currently the Vice Chair of Translational Research for the Department of Neurology and Directs the Neurosciences Translational Research Center at UT Southwestern.
Dr. Greenberg splits his clinical time between adult and pediatric patients, routinely consulting on the inpatient units of Clements and Zale Lipshy University Hospitals, Parkland, and Children’s Medical Center.
His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients.
In addition, Dr. Greenberg has led an effort to improve biorepository development and create uniform protocols for sample handling and analysis. As part of this initiative, his collaborative research has identified novel biomarkers that may be key to distinguishing between patients with various neurologic disorders.